Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-12-09 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力独立董事年报工作制度（2025年12月修订）
Governance Information Classification · 95% confidence The document is titled as an internal work system for independent directors related to the annual report process of the company. It outlines procedures, responsibilities, and communication protocols for independent directors during the preparation and auditing of the annual report. It does not contain actual financial data or the annual report itself, but rather governance and procedural guidelines related to the annual report. This fits best under Governance Information (CGR), which covers internal rules and governance practices. The document length is short (1082 characters), and it is not an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CGR with high confidence.
2025-12-09 Chinese
天士力对外捐赠管理制度
Governance Information Classification · 95% confidence The document is a detailed internal management policy titled '对外捐赠管理制度' (External Donation Management System) issued by 天士力医药集团股份有限公司. It outlines principles, scope, types, budgeting, decision procedures, and legal responsibilities related to the company's external donation activities. There is no indication that this is a financial report, regulatory filing, announcement, or any of the other specific filing types such as annual report, earnings release, or management report. Instead, it is a governance-related internal policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3044 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification.
2025-12-09 Chinese
天士力第九届董事会第16次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 9th Board of Directors of the company. It details voting results on various governance-related proposals, including amendments to the company charter, governance system revisions, anticipated related-party transactions, change of accounting firm, and notice of an upcoming shareholders meeting. The document references other announcements published on the stock exchange website for detailed content but itself primarily reports the board meeting decisions and voting outcomes. It does not contain financial statements, earnings data, or detailed management discussion. The focus on board meeting resolutions and governance matters aligns with the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a standalone announcement of board decisions, not a full report or presentation. Therefore, the appropriate classification is MANG with high confidence.
2025-12-09 Chinese
天士力信息披露暂缓与豁免业务管理办法（2025年12月修订）
Regulatory Filings Classification · 95% confidence The document is titled '信息披露暂缓与豁免业务管理办法' which translates to 'Information Disclosure Delay and Exemption Management Measures' for a company. It outlines internal policies and procedures for delaying or exempting disclosure of information, including legal references, internal approval processes, confidentiality commitments, and record-keeping. There are no financial statements, earnings data, or report summaries. The document is a regulatory or compliance policy document related to information disclosure management rather than a financial report or announcement. It is also relatively short (4269 characters) and does not contain any report or announcement of voting results, dividends, or capital changes. This fits best under Regulatory Filings (RNS) as a compliance document that does not fit other categories.
2025-12-09 Chinese
天士力董事、高级管理人员离职管理制度
Board/Management Information Classification · 95% confidence The document is titled '董事、高级管理人员离职管理制度' which translates to 'Board and Senior Management Resignation Management System'. It details the rules and procedures regarding the resignation, responsibilities, and shareholding management of the company's directors and senior management personnel. There is no financial data, no mention of financial results, no regulatory filings or announcements of voting results, no audit or legal proceedings information. The content is focused on governance policies related to board and management personnel. Therefore, it fits best under 'Board/Management Information' (MANG) as it concerns management changes and related governance rules.
2025-12-09 Chinese
天士力独立董事制度（2025年12月修订）
Governance Information Classification · 95% confidence The document is a detailed policy document titled "独立董事制度" (Independent Director System) for TianShiLi Pharmaceutical Group Co., Ltd. It outlines the governance structure, roles, responsibilities, appointment, and operational procedures of independent directors within the company. The content focuses on corporate governance practices, board structure, and regulatory compliance related to independent directors. There is no financial data, earnings information, voting results, or announcements of report publications. The document is not a report of financial results, nor is it a regulatory filing or announcement. It fits best under Governance Information (CGR) as it details the company's internal rules and governance practices regarding independent directors.
2025-12-09 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.